Mohamed Mansoor, M.A.; Zhu, X.; Ashiqueali, S.A.; Alam, M.T.; Winiarska, H.; Pazdrowski, P.; Kaminski, F.; Copik, A.; Masternak, M.M.; Kuznar-Kaminska, B.
Circulating microRNAs as a Prognostic Tool to Determine Treatment Efficacy in Lung Cancer Patients Undergoing Pembrolizumab PD-1 Blockade Immunotherapy. Cancers 2024, 16, 4202.
https://doi.org/10.3390/cancers16244202
AMA Style
Mohamed Mansoor MA, Zhu X, Ashiqueali SA, Alam MT, Winiarska H, Pazdrowski P, Kaminski F, Copik A, Masternak MM, Kuznar-Kaminska B.
Circulating microRNAs as a Prognostic Tool to Determine Treatment Efficacy in Lung Cancer Patients Undergoing Pembrolizumab PD-1 Blockade Immunotherapy. Cancers. 2024; 16(24):4202.
https://doi.org/10.3390/cancers16244202
Chicago/Turabian Style
Mohamed Mansoor, Mishfak A., Xiang Zhu, Sarah Aslam Ashiqueali, Md Tanjim Alam, Hanna Winiarska, Pawel Pazdrowski, Filip Kaminski, Alicja Copik, Michal M. Masternak, and Barbara Kuznar-Kaminska.
2024. "Circulating microRNAs as a Prognostic Tool to Determine Treatment Efficacy in Lung Cancer Patients Undergoing Pembrolizumab PD-1 Blockade Immunotherapy" Cancers 16, no. 24: 4202.
https://doi.org/10.3390/cancers16244202
APA Style
Mohamed Mansoor, M. A., Zhu, X., Ashiqueali, S. A., Alam, M. T., Winiarska, H., Pazdrowski, P., Kaminski, F., Copik, A., Masternak, M. M., & Kuznar-Kaminska, B.
(2024). Circulating microRNAs as a Prognostic Tool to Determine Treatment Efficacy in Lung Cancer Patients Undergoing Pembrolizumab PD-1 Blockade Immunotherapy. Cancers, 16(24), 4202.
https://doi.org/10.3390/cancers16244202
